Pharma BD Deal Intelligence
Roche Holding AG / GlycArt Biotechnology AG
2005 · Acquisition/Merger · $182M · Complete
Announcement Sentiment
100
Strongly positive
Roche acquires Swiss antibody-engineering specialist GlycArt for ~CHF 235M (~$181.6M); GlycoMAb glycosylation platform - basis for obinutuzumab (Gazyva).
Key facts
- Announced Jul 19, 2005
- Deal value $182M
- Deal type Acquisition/Merger
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals